RxDoctor Payments Data

Jennifer Paulsen

Family · Spokane, WANPI 1891409090

Payments from drug & device makers

$870in general payments, 2019–2025

Across 33 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$209
  • Lilly USA, LLC$179
  • Novo Nordisk$123
  • Phathom Pharmaceuticals, Inc.$114
  • AstraZeneca$62
  • Johnson & Johnson$43
  • plus $141 from 5 others

What the payments were for

  • Food & beverage$870100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$870 in reported general payments places this provider in the 75th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$30,337
Medicare patients
163
Services billed
459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban23$22,991
MounjaroTirzepatide17$18,093
MyrbetriqMirabegron11$13,361
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen86$1,692
Gabapentin73$1,535
SynthroidLevothyroxine Sodium18$1,208
Levothyroxine Sodium138$1,190
Pentoxifylline12$1,145
Losartan Potassium117$1,042
Omeprazole54$1,001
Albuterol Sulfate HfaAlbuterol Sulfate29$916
Doxycycline Monohydrate15$685
Atorvastatin Calcium114$664
Tamsulosin Hcl45$590
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$43$22,99123 claims
Lilly USA, LLCMounjaro$179$18,09317 claims
AbbVieSynthroid$209$1,20818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,706 family providers in Washington.

Other family in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →